[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"food-allergies\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:food-allergies":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,73,99,129,151],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100652017","oral-immunotherapy-for-children-with-cows-milk-allergy-100652017",false,"NCT07768696","Oral Immunotherapy for Children With Cow's Milk Allergy","Oral Immunotherapy for Children With Cow's Milk Allergy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 6 to 18 months\n* Cow's milk allergy confirmed at an oral food challenge\n* Reaction threshold below 300 mg of cow's milk protein at the oral food challenge\n* Specific IgE to cow's milk \\> 0.35 kU\u002FL\n* High risk of persistent allergy to cow's milk (based on defined criteria)\n* Family motivated for oral immunotherapy following shared decision-making using a decision aid\n\nExclusion Criteria:\n\n* Uncontrolled asthma, eczema, rhino-conjunctivitis, urticaria, or eosinophilic esophagitis\n* Treatment with biologic or immunosuppressive medication\n* Non-Danish-speaking families\n* Anticipated non-adherent families","ALL","6 Months","18 Months",{"count":20,"type":21},56,"ESTIMATED","INTERVENTIONAL",[24],"NA","This clinical trial aims to investigate if oral immunotherapy can help children with cow's milk allergy tolerate cow's milk.\n\nChildren aged 6-18 months can take part in the trial.\n\nMain question: What percentage of children can tolerate cow's milk after oral immunotherapy, compared with children who avoid cow's milk?\n\nChildren are assigned to these two groups by chance.\n\nChildren receiving oral immunotherapy will:\n\n* Take a small, increasing amount of cow's milk daily for 1-1.5 years\n* Attend clinic or online visits each time the dose is increased\n* Record missed doses\n\nAll children will:\n\n* Provide blood samples to measure allergy-related markers\n* Undergo an oral food challenge with cow's milk after 1-1.5 years to assess how much they can tolerate\n* Report allergic reactions (parent-reported)\n* Complete questionnaires (parent-reported)\n* Participate in an end-of-study telephone interview with an allergy nurse (parent-reported)",[27,28,29],"Milk Allergy, Cow's","Food Allergy in Children","Food Allergies",[31,32,33],"Oral immunotherapy","OIT","Desensitization","NOT_YET_RECRUITING","2026-08-12",{"date":37,"type":38},"2026-08-17","ACTUAL",{"date":40,"type":21},"2026-09",{"date":42,"type":21},"2031-09",{"name":44,"class":45},"Laura Ozer Kettner","OTHER",5,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100651607","multi-food-oral-immunotherapy-for-peanut-and-tree-nuts-100651607","NCT07764159","Multi-Food Oral Immunotherapy for Peanut and Tree Nuts","An Open-Label, Multicenter, Randomized Clinical Trial Evaluating the Efficacy and Safety of Oral Multi-Food Immunotherapy With Peanut and Tree Nuts Protein Mixtures","Inclusion Criteria:\n\n* Age 1-12 years;\n* Confirmed allergy to at least two allergens included in the protocol, i.e., peanut and\u002For tree nuts: cashew, walnut, hazelnut, and almond;\n* Positive skin prick test (SPT) (wheal diameter ≥ 3 mm) and\u002For specific IgE (sIgE) level \\> 0.35 kUA\u002FL for at least two of the analyzed allergens;\n* Positive OFC-1 (oral food challenge) of grade I-IV according to the WAO classification for at least two allergens, with a positive reaction occurring after administration of a dose ≥ 3 mg and ≤ 3000 mg of allergen protein;\n* Participants may be enrolled based on the abbreviated procedure as outlined in the study description;\n* Written informed consent obtained from a legal guardian, and, where applicable, assent from the child in accordance with their age and level of maturity;\n* Good prognosis for compliance and cooperation of the patient and their caregivers.\n\nExclusion Criteria:\n\n* Allergic reaction at the lowest challenge dose of 1 mg of allergen protein for any allergen, or no allergic reaction after administration of the maximum dose of 3000 mg of allergen protein for at least four of the analyzed allergens;\n* History of anaphylaxis with a grade V reaction according to the WAO classification, either during an oral food challenge or in the patient's medical history;\n* Severe asthma;\n* Poorly controlled asthma according to GINA 2025 (lack of symptom control and\u002For ≥2 exacerbations requiring systemic glucocorticoids or ≥1 exacerbation requiring hospitalization within the last 12 months), or in children able to perform spirometry: FEV1 \\\u003C -1.64 Z-score and\u002For FEV1\u002FFVC \\\u003C -1.64 Z-score;\n* Eosinophilic gastrointestinal disease;\n* Other chronic diseases requiring ongoing treatment which, in the investigator's opinion, may increase the risk associated with study participation or interfere with the interpretation of results, including severe cardiac disease, epilepsy, metabolic disorders, or diabetes;\n* Previous immunotherapy with food allergens;\n* Concurrent immunotherapy with aeroallergens;\n* Treatment with biologic agents, beta-blockers, ACE inhibitors, or calcium channel blockers;\n* Oral corticosteroid therapy meeting any of the following criteria: daily treatment for \\>1 month within the last 12 months; at least two courses lasting ≥7 days within the last 12 months; one course lasting ≥7 days within the last 3 months;\n* Lack of consent to participate in the study or insufficient cooperation of the patient and\u002For caregivers. In such cases, patients will receive standard medical care, including allergen avoidance and provision of emergency medication.\n\nWell-controlled asthma, allergic rhinitis, and atopic dermatitis are not exclusion criteria.","1 Year","12 Years",{"count":57,"type":21},39,[24],"This study aims to evaluate the efficacy and safety of multi-food oral immunotherapy (multi-OIT) using peanut and tree nuts proteins in children with confirmed food allergy to at least two allergens. Participants will be randomized in a 2:1 ratio to receive either multi-OIT or standard management consisting of an elimination diet. The primary objective is to evaluate immunotherapy efficacy defined as achieving tolerance to a cumulative dose of 4444 mg of protein during an oral food challenge (OFC-2) for at least one allergen that elicited a reaction during baseline challenge (OFC-1), compared with the control group. Secondary outcomes include the proportion of participants tolerating multiple allergens at the target cumulative dose; the incidence, type, and severity of adverse events classified according to the World Allergy Organization (WAO) grading system; changes in immunological parameters, including allergen-specific IgE and IgG4 levels; changes in skin prick test responses; changes in the quality of life of patients and their families.",[29,28,61,62,63],"Peanut Allergies","Tree Nut Allergies","Oral Immunotherapy for Food Allergy","2026-08-11",{"date":66,"type":38},"2026-08-13",{"date":40,"type":21},{"date":69,"type":21},"2031-12",{"name":71,"class":45},"Medical University of Warsaw",4,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100620558","a-long-term-observational-follow-up-study-of-children-and-young-people-who-underwent-an-18-month-course-of-oral-immunotherapy-treatment-for-peanut-egg-or-milk-allergy-5-15-years-post-treatment-100620558","NCT07359183","A Long Term, Observational Follow-Up Study of Children and Young People Who Underwent an 18-Month Course of Oral Immunotherapy Treatment for Peanut, Egg or Milk Allergy (5-15 Years Post-Treatment)","Long Term Outcomes Associated With Attainment of Remission Following Oral Immunotherapy to Peanut, Egg and Cow's Milk (LPEM Study)","LPEM","Inclusion Criteria:\n\n* Previous participant of PEAT, PrEMO, PPOIT-001 or PPOIT-002 parent study\n* Received at least one dose of OIT treatment in the parent study\n* Written informed consent from participant and\u002For parent\u002Fguardian (if below 18 years of age)\n\nExclusion Criteria:\n\n-Have any conditions that, in the opinion of the investigator, precludes participation for reason of safety",{"count":82,"type":21},147,"OBSERVATIONAL","The goal of this observational study is to learn about the long-term outcomes of children and young people who underwent an 18-month course of oral immunotherapy (OIT) treatment for peanut, egg or milk allergy. It aims to:\n\n• Compare long-term changes in health-related quality of life (HRQL) at 5-15 years after stopping OIT in participants who achieved remission and those who did not.\n\nParticipants will attend a single follow-up visit for:\n\n* A blood test\n* Skin prick test (SPT)\n* Allergy questionnaires",[29,61,86,87],"Egg Allergy","Milk Allergy","RECRUITING","2026-01-29",{"date":91,"type":38},"2026-02-02",{"date":93,"type":38},"2026-01-13",{"date":95,"type":21},"2027-01",{"name":97,"class":45},"Murdoch Childrens Research Institute",1,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":111,"conditions":112,"keywords":113,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":4},"100598585","omalizumab-for-plant-food-allergy-due-to-sensitization-to-ltp-or-profilin-100598585","NCT07073404","Omalizumab for Plant-Food Allergy Due to Sensitization to LTP or Profilin","Omalizumab for the Monotherapy Treatment of Patients With Allergy to Foods of Plant Origin Due to Sensitization to Lipid Transfer Proteins (LTPs) and Profilin","Omlyclo","Inclusion Criteria:\n\n* Males or females aged 14-55 years who sign the informed consent (IC) for the study and Biobank sample storage.\n* Allergy to plant foods due to sensitisation to LTP, patients allergic to profilin confirmed by a suggestive clinical history, positive skin tests and specific IgE to Pru p 3 (peach LTP) and Pho d 2 (Phoenix dactylifera profilin).\n* Positive oral challenge test (OPT) to peach and at least one other food in patients allergic to LTP and positive oral challenge test to melon and at least one other food in patients allergic to profilin.\n* Selection of a group of LTP-allergic individuals with therapeutic failure after treatment with ITSL-Pru p 3.\n\nExclusion Criteria:\n\n* Pregnancy and lactation.\n* Immunological diseases; treatment with immunomodulatory and\u002For blocking drugs.\n* Mental illness, which makes it impossible to follow and adhere to treatment (e.g. major depression, psychosis, etc.).\n* Severe atopic dermatitis according to SCORAD 5: FEV1\\\u003C70% (this test will be carried out as a priority in patients with a previous diagnosis of asthma).\n* Inflammation in the oral cavity with severe symptoms, as well as with oral surgery in the previous 7 days.\n* Immunotherapy with pollens in the previous 2 years.\n* Subjects unable to comply with the schedule of visits during the study, as well as due to the consumption of the food under investigation, for example, due to work difficulties.","14 Years","55 Years",{"count":110,"type":21},37,"Omalizumab has demonstrated efficacy, increasing the tolerance threshold in patients with multiple food allergies, as well as reducing the risk of severe reactions when used as monotherapy. This favors improving the reactivity profile of patients with food allergy. In our setting, plant allergy caused by sensitization to panallergens such as lipid transfer proteins (LTPs) and profilins entails important limitations for the consumption of a healthy diet due to the extensive dietary restrictions.\n\nThe main objective of this project is to analyze the efficacy of treatment with omalizumab administered every 2-4\u002Fweeks, used in monotherapy in patients with plant allergy due to sensitization to profilin and LTPs and those patients in whom sublingual immunotherapy with Pru p 3 (peach LTP), has not been effective, by performing a before-after study we will evaluate the changes in clinical reactivity to LTP (peach) and profilin (melon) and the changes immunological effect after omalizumab intervention. In addition, we will evaluate the changes in reactivity to at least one food other than peach and melon in the different sensitization profiles.",[29],[114,115,116,117,118,119],"Omalizumab","FOOD ALLERGIES","LTP","Profilins","Allergy desensitization","Lipid transfer proteins","2025-08-06",{"date":122,"type":38},"2025-08-12",{"date":124,"type":21},"2026-01",{"date":126,"type":21},"2027-12",{"name":128,"class":45},"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":107,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":139,"conditions":140,"keywords":141,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":150,"locationsCount":98},"100592745","endophenotyping-for-plant-based-food-allergy-diagnosis-tolerance-biomarkers-and-mechanisms-in-microneedle-immunotherapy-100592745","NCT06997432","Endophenotyping for Plant-based Food Allergy Diagnosis, Tolerance Biomarkers, and Mechanisms in Microneedle Immunotherapy","Study of the Clinical and Immunological Implications of Maintaining in the Diet the Maximum Tolerated Dose Identified in a Controlled Food Exposure Test According to the Sensitization Profile to LTPs","Inclusion Criteria:\n\n* Women and men\n* 14-65 years-old\n* Peach allergy due to sensitization to LTP confirmed by skin tests and\u002For IgEe positive to Pru p 3.\n* Sign informed consent.\n\nExclusion Criteria:\n\n* Pregnant of lactating women.\n* Patients with immunological diseases, mental illness or severe atopic dermatitis.\n* Patients treated with immunomodulators and\u002For β-blockers\n* Patients with forced expiratory volume (FEV1)\\\u003C70%.","65 Years",{"count":138,"type":21},32,"In relation to the prognosis of vegetable FA (VFA), in contrast to other food allergies (FA), which disappear naturally with time, VFA tends to persist into adulthood and to the appearance of new sensitizations to other vegetables. The paradigm of early intervention in patients with risk factors for developing FA has changed in recent years, with evidence that maintaining a controlled diet with foods with potential allergic risk in a population of children at risk has shown efficacy in early intervention. An important aspect would be the selection of the dose of the food to be included in the diet. In this sense, recent studies on the standardization of the double-blind placebo-controlled oral challenge test (DBPCFC) in allergic patients to Lipid Transfer Proteins (LTP) with known amounts of Pru p 3 (peach LTP), have observed that the maximum tolerated dose (MTD) was equivalent to 40 grams of peach with skin. Based on these results and those obtained in the pediatric population, this study aims to evaluate whether the maintenance in the diet of a DMT evaluated in a DBPCFC could influence tolerance (desensitization) to the food at both clinical and immunological levels.",[29],[142,118,143],"Vegetable food allergy","Lipid Transfer Proteins","2025-05-21",{"date":146,"type":38},"2025-05-30",{"date":148,"type":21},"2025-06",{"date":126,"type":21},{"name":128,"class":45},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":16,"minAge":159,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":165,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":179},"100586549","food-challenge-at-home-or-in-medical-practice---the-foodchomp-study-100586549","NCT06916819","Food Challenge at Home or in Medical Practice - the FoodCHOMP Study","Food Challenge at Home or in Medical Practice - a Multi-center Randomized Control Trial - FoodCHOMP Study","CHOMP","Inclusion Criteria:\n\n1. Negative (\\\u003C3mm) fresh or extract skin testing to the food implicated within their allergy label\n2. Aged greater than 18 years\n\nExclusion Criteria:\n\n* Evidence of prior sensitisation to challenge food 0 Defined as previously positive skin testing or allergen specific IgEs if available\n* Pregnancy\n* Patients with poorly controlled asthma - defined as an ACQ5 scores \\>1 at the time of enrolment\n* Patients with a history of food reactions that is not-consistent with an IgE mediated process; i.e. exclusively gastrointestinal symptoms, FPIES\n* Patients with a clear history of food-dependent exercise induced anaphylaxis\n* Patients on a concurrent medication which may influence the outcome of the challenge;\n* Antihistamine therapy; Patients receiving more than stress dose steroids (i.e. \\> 50mg QID hydrocortisone \\[or steroid equivalent\\]); Omalizumab\n* Any other illness that, in the investigator's judgement, will substantially increase the risk associated with subject's participation in this study","18 Years",{"count":161,"type":21},120,[24],"This is a pilot, multi-centre, randomised clinical trial evaluating the safety and feasibility of a home-based oral food challenge in adults with low-risk food allergy labels. Eligible participants are aged 18 years or older and have a self-reported food allergy with negative skin prick testing to the implicated food. Participants will be randomised to either a home-based or standard in-clinic food challenge. The primary aim is to determine the safety of home challenges, measured by the rate of immune-mediated adverse events. Secondary aims include feasibility of recruitment and delivery, protocol adherence, quality of life, and food reintroduction outcomes.",[29],[166,167,168],"Food allergy","Food allergy label","Food Challenge","2025-04-15",{"date":171,"type":38},"2025-04-17",{"date":173,"type":38},"2025-04-16",{"date":175,"type":21},"2026-12-01",{"name":177,"class":178},"Austin Health","OTHER_GOV",2]